Wing‐Kai Chan

4.8k total citations · 2 hit papers
57 papers, 3.2k citations indexed

About

Wing‐Kai Chan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Wing‐Kai Chan has authored 57 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Wing‐Kai Chan's work include Cancer Treatment and Pharmacology (14 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Wing‐Kai Chan is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Hepatocellular Carcinoma Treatment and Prognosis (9 papers) and Colorectal Cancer Treatments and Studies (8 papers). Wing‐Kai Chan collaborates with scholars based in Taiwan, United States and New Zealand. Wing‐Kai Chan's co-authors include Pan‐Chyr Yang, Ang Yuan, Sung‐Liang Yu, Yee Chao, Jeremy J.W. Chen, Jin‐Yuan Shih, Hsuan‐Yu Chen, Chih‐Yi Chen, Gee‐Chen Chang and Hsuan‐Yu Chen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Wing‐Kai Chan

56 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Five-Gene Signature and Clinical Outcome in Non–Small-Cell Lung Cancer

2007 693 citations Sung‐Liang Yu, Ang Yuan et al. profile →
Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

2012 429 citations Kang‐Yi Su, Hsuan‐Yu Chen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wing‐Kai Chan Taiwan	22	1.4k	1.4k	1.2k	828	307	57	3.2k
O. Kisker Germany	28	2.0k 1.4×	988 0.7×	876 0.7×	620 0.7×	555 1.8×	43	3.3k
Daniel S.W. Tan Singapore	34	1.8k 1.3×	1.3k 1.0×	1.9k 1.6×	965 1.2×	258 0.8×	159	4.1k
Petr Kavan Canada	29	1.5k 1.0×	1.0k 0.7×	1.1k 1.0×	876 1.1×	390 1.3×	141	4.4k
Peter Vermeulen Belgium	35	2.3k 1.6×	1.4k 1.0×	776 0.7×	1.3k 1.5×	393 1.3×	79	4.0k
Herbert H. Loong Hong Kong	30	1.5k 1.0×	790 0.6×	1.3k 1.1×	548 0.7×	412 1.3×	163	3.0k
S. Kakolyris Greece	32	1.9k 1.3×	1.0k 0.7×	925 0.8×	816 1.0×	254 0.8×	90	3.0k
Annarita Destro Italy	29	1.5k 1.0×	1.2k 0.9×	1.6k 1.3×	621 0.8×	449 1.5×	58	3.7k
Anthony M. D’Amelio United States	16	1.4k 1.0×	1.4k 1.0×	1.6k 1.3×	697 0.8×	115 0.4×	37	2.9k
Hiroyasu Kaneda Japan	30	2.3k 1.6×	1.1k 0.8×	1.6k 1.4×	445 0.5×	253 0.8×	118	3.5k
Ignacio Gil‐Bazo Spain	31	1.1k 0.8×	1.2k 0.9×	1.0k 0.9×	805 1.0×	169 0.6×	103	2.6k

Countries citing papers authored by Wing‐Kai Chan

Since Specialization

Citations

This map shows the geographic impact of Wing‐Kai Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wing‐Kai Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wing‐Kai Chan more than expected).

Fields of papers citing papers by Wing‐Kai Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wing‐Kai Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wing‐Kai Chan. The network helps show where Wing‐Kai Chan may publish in the future.

Co-authorship network of co-authors of Wing‐Kai Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Wing‐Kai Chan. A scholar is included among the top collaborators of Wing‐Kai Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wing‐Kai Chan. Wing‐Kai Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Medlicott, Natalie J., Yi Wang, Noelyn Hung, et al.. (2024). A Sensitive Assay for Unbound Docetaxel Using Ultrafiltration plus HPLC-MS and Its Application to a Clinical Study. Pharmaceutics. 16(5). 602–602. 1 indexed citations

Dai, Ming‐Shen, Ta‐Chung Chao, Chang‐Fang Chiu, et al.. (2023). Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. Therapeutic Advances in Medical Oncology. 15. 2628416–2628416. 2 indexed citations

Hong, Jin‐Bon, Po‐Yuan Wu, Albert Qin, et al.. (2022). Topical Tirbanibulin, a Dual Src Kinase and Tubulin Polymerization Inhibitor, for the Treatment of Plaque-Type Psoriasis: Phase I Results. Pharmaceutics. 14(10). 2159–2159. 4 indexed citations

He, Zhijian, Christopher Jackson, Sanjeev Deva, et al.. (2022). Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors. CPT Pharmacometrics & Systems Pharmacology. 11(7). 867–879. 4 indexed citations

Jackson, Christopher, Eva Segelov, Hans Prenen, et al.. (2021). Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study. British Journal of Clinical Pharmacology. 87(12). 4670–4680. 11 indexed citations

Su, Kang‐Yi, Hsuan‐Yu Chen, Ker-Chau Li, et al.. (2012). Pretreatment Epidermal Growth Factor Receptor ( EGFR ) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 30(4). 433–440. 429 indexed citations breakdown →

Pan, Szu‐Hua, Hsuan-Yu Chen, Yih‐Leong Chang, et al.. (2011). The ability of LCRMP-1 to promote cancer invasion by enhancing filopodia formation is antagonized by CRMP-1. Journal of Clinical Investigation. 121(8). 3189–3205. 63 indexed citations

Shen, Li‐Jiuan, et al.. (2011). Economic benefits of sponsored clinical trials on pharmaceutical expenditures at a medical center in Taiwan. Contemporary Clinical Trials. 32(4). 485–491. 26 indexed citations

Hong, Tse‐Ming, Yuh-Ling Chen, Yi-Ying Wu, et al.. (2007). Targeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer. Clinical Cancer Research. 13(16). 4759–4768. 163 indexed citations

10.

Ho, Chao‐Chi, Wei‐Yu Liao, Yung‐Ming Chen, et al.. (2007). TREM-1 Expression in Tumor-associated Macrophages and Clinical Outcome in Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 177(7). 763–770. 122 indexed citations

11.

Wang, Chi-Chung, Meng-Feng Tsai, Tse‐Ming Hong, et al.. (2007). Synergistic Activation of the Tumor Suppressor, HLJ1, by the Transcription Factors YY1 and Activator Protein 1. Cancer Research. 67(10). 4816–4826. 50 indexed citations

12.

Chi, Kwan‐Hwa, Jeffrey N. Myers, Kuan‐Chih Chow, et al.. (2001). Phase II Trial of Systemic Recombinant Interleukin-2 in the Treatment of Refractory Nasopharyngeal Carcinoma. Oncology. 60(2). 110–115. 23 indexed citations

13.

Chan, Wing‐Kai, et al.. (1997). A Phase II Study of Carboplatin in Nasopharyngeal Carcinoma. Oncology. 54(3). 203–207. 9 indexed citations

14.

Chou, F.I., Kang Fang, Cheng‐Yu Chung, et al.. (1995). Lipiodol uptake and retention by human hepatoma cells. Nuclear Medicine and Biology. 22(3). 379–386. 27 indexed citations

15.

Lai, Kwok-Hung, Yang‐Te Tsai, Shou‐Dong Lee, et al.. (1989). Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection. Cancer Chemotherapy and Pharmacology. 23(1). 54–6. 23 indexed citations

16.

Levi, John A., et al.. (1987). Randomised study of ticarcillin, cefamandole with or without tobramycin in febrile, neutropenic patients with solid tumors. Medical and Pediatric Oncology. 15(1). 7–13. 1 indexed citations

17.

Chan, Wing‐Kai, R. S. Aroney, John A. Levi, et al.. (1982). Four-drug combination chemotherapy for advanced cervical carcinoma. Cancer. 49(12). 2437–2440. 9 indexed citations

18.

Aroney, R. S., David Bell, Wing‐Kai Chan, D. Dalley, & John A. Levi. (1982). Alternating non-cross-resistant combination chemotherapy for small cell anaplastic carcinoma of the lung. Cancer. 49(12). 2449–2454. 18 indexed citations

19.

Aroney, R. S., D. Dalley, Wing‐Kai Chan, David Bell, & J.A. Levi. (1981). Meningeal carcinomatosis in small cell carcinoma of the lung. The American Journal of Medicine. 71(1). 26–32. 68 indexed citations

20.

Aroney, R. S., D. Dalley, Wing‐Kai Chan, David Bell, & John A. Levi. (1981). Methyl‐CCNU, 6‐Thioguanine, and 5‐fluorouracil in advanced colorectal cancer. Medical and Pediatric Oncology. 9(2). 181–186. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact